Adcentrx Therapeutics. a Shanghai-San Diego startup, closed a $50 million Series A financing to develop next-gen ADC candidates for cancer and other serious diseases. The company will accelerate breakthroughs in protein conjugate therapies, which combine the precision of biologics with powerful small molecule payloads. The financing was led by CBC Group (formerly C-Bridge Capital). Zoo Capital, Boyu Capital's venture arm, also joined the round. More details.... Share this with colleagues: // //